ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment…
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment…
The Company is recognized for its commitment to employees’ well-being MALVERN, Pa., May 15, 2023…
Appointment to Enhance Board’s Expertise Across Investments, Business Development and Capital Markets Kelly Anderson Hillstream BioPharma…
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones…
Upcoming Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010,…
– Top-line data from Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) in NASH…
HAMPTON, N.J., May 15, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preclinical…
– Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients…
YONKERS, N.Y., May 15, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
Fort Lee, NJ, May 15, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis”…
9 subjects enrolled into the OPMD clinical development program HAYWARD, Calif., May 15, 2023 (GLOBE…
SAN FRANCISCO, May 15, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced…
Company to host Investor Update call on June 14, 2023 to review and discuss the…
BOTHELL, Wash., May 15, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the…
Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members…
Shockwave C2+ Catheter Expands Utility of IVL in Calcified Coronary Arteries SANTA CLARA, Calif., May…
SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) — Locanabio, Inc., a genetic medicines company developing…
End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path…
Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022 Global End…
Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with…